al gunduz sales intro to 2008
DESCRIPTION
Sales goals for Al Gunduz - 2008TRANSCRIPT
Sales Meeting – Western Region – January 14 2008
Focus: Taxane Related Products
Why pursue Taxane based products?
“This places screams engineering – engineering is your strong point” - Doug Johnson, Allos:
Why pursue Taxane based products?
Taxane based products require large amounts of engineering• Combination of aqueous & lipid phases• Homogenization• Microfluidization• Possible cytotoxic lyophilization?
Why pursue Taxane based products?
Docetaxel to expire 2010
Vinorelbine – off-patent since 2003
Lipid-Soluble API Formulation
SN-38
NeoPharm, Inc.
Enzon Pharmaceuticals, Inc
Taxanes
RTI, International
Cell Therapeutics, Inc.
Azaya Therapeutics
Small to Mid-Pharma with Ongoing Clinical Trials
Docetaxel
NovaceaZeneus PharmaGenta IncorporatedPoniard PharmaceuticalsSeattle Genetics, Inc.GPC BiotechProacta, IncorporatedKeryx BiopharmaceuticalsInfinity Pharmaceuticals, Inc.Cytokinetics, Inc.Semafore Pharmaceuticals Inc.
RTI, InternationalCell Therapeutics, Inc.Azaya TherapeuticsMethylGeneAscenta TherapeuticsCell GenesysTitan PharmaceuticalsCytogen CorporationTibotec TherapeuticsONYX PharmaceuticalsAmpliMed Corporation
CPT-11
EMD Serono, Inc.Wellstat TherapeuticsAdnexusImClone Systems
Celgene CorporationYM BioSciencesDynavax Technologies Corporation
Why pursue Taxane based products?
Taxane based products require large amounts of engineering• Combination of aqueous & lipid phases• Homogenization• Microfluidization• Possible cytotoxic lyophilization?
How widespread are Taxane based products How widespread are Taxane based products?
Docetaxel
Docetaxel- 809 on-going studies
Vinorelbine- 160 on-going studies
CPT-11- 210 on-going studies
SN-38- 13 on-going studies
Recent News
Docetaxel
02 Jan 2008 NEOPHARM, Inc. today announced that it has filed an investigational new drug application with the FDA for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy
WAUKEGAN, IL, USA | January 2, 2008 | NEOPHARM, Inc. (NASDAQ:NEOL) today announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy.
“Promote it and they will come”
HCM to PaperazziDistance 700 ft
Current HCM Client to closest CMODistance 500 ft